CA2469925A1 - Carnitine in the treatment of geriatric depression - Google Patents

Carnitine in the treatment of geriatric depression Download PDF

Info

Publication number
CA2469925A1
CA2469925A1 CA002469925A CA2469925A CA2469925A1 CA 2469925 A1 CA2469925 A1 CA 2469925A1 CA 002469925 A CA002469925 A CA 002469925A CA 2469925 A CA2469925 A CA 2469925A CA 2469925 A1 CA2469925 A1 CA 2469925A1
Authority
CA
Canada
Prior art keywords
carnitine
acid
medicament
pme
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002469925A
Other languages
English (en)
French (fr)
Inventor
Jay W. Pettegrew
Samuel Gershon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2469925A1 publication Critical patent/CA2469925A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002469925A 2002-02-07 2003-01-23 Carnitine in the treatment of geriatric depression Abandoned CA2469925A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35432302P 2002-02-07 2002-02-07
US60/354,323 2002-02-07
PCT/IT2003/000023 WO2003066041A1 (en) 2002-02-07 2003-01-23 Carnitine in the treatment of geriatric depression

Publications (1)

Publication Number Publication Date
CA2469925A1 true CA2469925A1 (en) 2003-08-14

Family

ID=27734357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002469925A Abandoned CA2469925A1 (en) 2002-02-07 2003-01-23 Carnitine in the treatment of geriatric depression

Country Status (10)

Country Link
US (1) US20040009926A1 (https=)
EP (1) EP1471904A1 (https=)
JP (1) JP2005523269A (https=)
KR (1) KR20040083471A (https=)
AR (1) AR038350A1 (https=)
AU (1) AU2003219511A1 (https=)
CA (1) CA2469925A1 (https=)
MX (1) MXPA04007506A (https=)
PL (1) PL374082A1 (https=)
WO (1) WO2003066041A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7815894B2 (en) 2003-05-29 2010-10-19 Jay W. Pettegrew Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
MX2012014127A (es) 2010-06-16 2013-06-28 Sigma Tau Ind Farmaceuti Acetil-carnitina para uso en un metodo para incrementar neurogenesis en tejido nervioso.
EP3212191B1 (en) * 2014-10-28 2022-10-05 Medlab IP Pty Ltd. Treatment for depression and depressive disorders
US11918336B2 (en) * 2019-02-19 2024-03-05 King Abdullah University Of Science And Technology Reduced feature generation for signal classification based on position weight matrix
KR20230011999A (ko) 2020-05-15 2023-01-25 알파시그마 에스.피.에이. 메틸폴레이트를 포함하는 조성물
CA3238205A1 (en) * 2021-11-12 2023-05-19 Rajaram Samant A synergistic composition for activating intracellular secondary messenger(camp) pathway
CN117797134A (zh) * 2022-09-23 2024-04-02 合肥瀚微生物科技有限公司 一种4-tmap治疗或缓解抑郁症的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5879884A (en) * 1994-12-29 1999-03-09 Peroutka; Stephen J. Diagnosis of depression by linkage of a polymorphic marker to a segment of chromosome 19P13 bordered by D19S247 and D19S394
JP3425276B2 (ja) * 1995-08-11 2003-07-14 株式会社日立製作所 情報通知システム
JPH10143640A (ja) * 1996-11-15 1998-05-29 Nippon Lsi Card Kk 携帯コンピュータ及びそれを用いた情報管理システム並びにそれを用いた立体地図の作成方法
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism

Also Published As

Publication number Publication date
AR038350A1 (es) 2005-01-12
AU2003219511A1 (en) 2003-09-02
US20040009926A1 (en) 2004-01-15
JP2005523269A (ja) 2005-08-04
EP1471904A1 (en) 2004-11-03
KR20040083471A (ko) 2004-10-02
PL374082A1 (en) 2005-09-19
MXPA04007506A (es) 2004-11-10
WO2003066041A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
Renshaw et al. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study
Kato et al. Choline-containing compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder
Alger et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET.
Lin et al. Reduced glutamate neurotransmission in patients with Alzheimer's disease–an in vivo 13C magnetic resonance spectroscopy study
Willemsen et al. Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome
Friedman et al. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder
Starck et al. A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity
US8575219B2 (en) Compounds for the treatment of psychiatric or substance abuse disorders
Saywell et al. Brain magnetic resonance study of Mecp2 deletion effects on anatomy and metabolism
Whitman et al. Diagnosis and therapeutic evaluation of a pediatric case of cardiomyopathy using phosphorus-31 nuclear magnetic resonance spectroscopy
Ensenauer et al. Guanidinoacetate methyltransferase deficiency: differences of creatine uptake in human brain and muscle
Noga et al. Cortical gyral anatomy and gross brain dimensions in monozygotic twins discordant for schizophrenia
US20100010336A1 (en) Method and system for diagnosis of neuropsychiatric disorders including attention deficit hyperactivity disorder (adhd), autism, and schizophrenia
US20100041621A1 (en) Methods and compositions for improving cognitive performance
Blasi et al. Hippocampal neurochemical pathology in patients at first episode of affective psychosis: a proton magnetic resonance spectroscopic imaging study
Ostojic et al. Dietary guanidinoacetic acid increases brain creatine levels in healthy men
Moore et al. Effects of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study
Sylvain et al. Magnetic resonance spectroscopy in Niemann-Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin
CA2469925A1 (en) Carnitine in the treatment of geriatric depression
Frederick et al. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline
Jensen et al. Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients.
Graham et al. Magnetic resonance spectroscopy of N‐acetylaspartate in hypoxic–ischemic encephalopathy
Takahashi et al. Proton magnetic resonance spectroscopy to study the metabolic changes in the brain of a patient with Leigh syndrome
Astley et al. Magnetic resonance imaging and spectroscopy in fetal ethanol exposed Macaca nemestrina
US20100041620A1 (en) Methods for improving frontal brain bioenergetic metabolism

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued